Navigation Links
Amsterdam Molecular Therapeutics Reports Half Year Results 2008
Date:8/13/2008

Conference Call & Webcast Today at 2:00 p.m. CET

AMSTERDAM, August 13 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2008.

Highlights

- Positive results of pivotal trial for Glybera(R) (AMT-011)

for Hyperlipoproteinemia type I

- European patent for treatment of Non-Alcoholic Steatotic

Hepatitis

- License for treatment of Duchenne Muscular Dystrophy from La

Sapienza University, Rome, Italy

- License for prevention of immune response against treatment of

Hemophilia B from 'TIGET", San Raffaele Telethon Gene Therapy Institute,

Milan, Italy

- Collaboration with St. Jude Children's Research Hospital,

Memphis, Tennessee, USA, including license for treatment of Hemophilia B

- GMP manufacturing development: License for raising yields of

production platform from NIH, Bethesda, USA

- Key financial figures in line with guidance

- Cash & cash equivalents of EUR 43.1 million at June 30, 2008

- Independent supervisory board with three new members bringing

extensive knowledge and experience.

Results comparison

AMT's key financial figures are in line with the guidance that the company has given for 2008. The operating loss increased to EUR 9.1 million for the six months ended June 30, 2008, from EUR 7.2 million for the same period in 2007. This difference is primarily due to the increase of research & development costs to EUR 5.8 million from EUR 3.8 million in the same period of 2007. This increase is particularly related to the development work on the company's lead product Glybera(R) (AMT-011) and increased staffing for this and other programs. General and administrative costs decreased slightly to EUR 3.3 million from EUR 3.5 million for the same period in 2007 due to lower share-based payments.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Part of Next Biotech Index
2. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
3. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
5. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Molecular Biometrics Announces Results of Parkinsons Disease Research and Receipt of Grant From Michael J. Fox Foundation to Advance Diagnostic Technology
9. Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics
10. New Turbomolecular Pumping System From Varian, Inc. Delivers Portable, Dry, Ultra-high Vacuum.
11. Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... Calif., Jan. 5 Beckman Coulter, Inc. (NYSE: ... and marketer of products that simplify, automate, and ... Garrett, Beckman Coulter,s chairman, president and chief executive ... Morgan Healthcare Conference on Monday, January 12, 2009 ...
... - YM BioSciences Inc. (NYSE Alternext US:YMI, ... develops and commercializes differentiated products for patients ... clearance from Canadian regulatory authorities to initiate ... nimotuzumab, its EGFR-targeting antibody, in combination with ...
... and Development of Anti-Inflammatory Drugs Based on Collaborators, ... Jan. 5 Research published in Nature ... interactions between two small signaling proteins called chemokines ... development of atherosclerosis in mice. San Diego-based Carolus ...
Cached Biology Technology:YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 2YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 4YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 5YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 6YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 7Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice 2Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice 3
(Date:4/15/2014)... Biologists at UC San Diego have succeeded in ... hormone responsible for growth and resistance to drought. ... studies to determine how the hormone helps plants ... by the continuing increase in the atmosphere,s carbon ... achievement appears in the April 15 issue of ...
(Date:4/15/2014)... have found a less invasive way to extract ... study how the mouth,s natural defenses ward off ... immune cells (white blood cells known as "leukocytes") ... mouthor reject foreign tissues, such as in failed ... and preventing such health issues as oral cancers, ...
(Date:4/15/2014)... (KNAW) has announced the names of five internationally renowned ... million US dollars prize money in total). The laureates ... science. , This year marks the 50th anniversary of ... Erwin Chargaff in 1964. , KNAW juries have ... , Christopher M. Dobson, John Humphrey Plummer ...
Breaking Biology News(10 mins):Biologists develop nanosensors to visualize movements and distribution of plant hormone 2New method isolates immune cells for researchers to study how they ward off oral diseases 2Five scientists awarded prestigious Heineken Prizes 2
... are the surprising culprits in delivering pollutants ?through their ... study shows. , The most common form of wildlife ... of the human-made contaminants to some coastal ecosystems, the ... pollutants such as mercury and DDT to as much ...
... discovered a novel way in which the brain size ... a signaling pathway that controls the orientation in which ... The way these cells are sliced during development is ... gives rise to two mature neurons that are incapable ...
... begun to clarify how one of the body's molecules controls ... and on to tissues to fight infection -- a crucial ... and causing autoimmune diseases. , The traffic control system -- ... on T cells -- usually prevents T cells from launching ...
Cached Biology News:Industrial contaminants spread by seabirds in High Arctic, new Canadian study shows 2Brain size may depend upon how neural cells are cleaved 2Brain size may depend upon how neural cells are cleaved 3Discovery of T-cell 'traffic control' boosts new drug promise 2Discovery of T-cell 'traffic control' boosts new drug promise 3Discovery of T-cell 'traffic control' boosts new drug promise 4
... coli containing a clone of the human Topoisomerase ... II alters the topological state of nucleic acids ... transient break which generates a separate DNA helix ... DNA passage mechanism, the enzyme can relax negatively ...
RNase-Free DNase 50 l...
supplied with 10x reaction buffer...
... RNase H degrades, as an endoribonuclease, ... DNA hybrids of natural origin, e.g. ... synthetic complexes, e.g. poly(A) x poly(dT). ... and 3-OH termini. Nearly no activity ...
Biology Products: